[THE INVESTOR] As of Oct. 19, Genic
(123330) rose 3.68% to 19,700 won (US$17.52). It had declined 6% through the past month. Standard deviation, the risk index for stock price, was 3.1% on the same period of time over one month.
" src="http://webchart.thinkpool.com/research/FArrowChart/A12333020161019.gif" /> | | | - The Return On Risk, -1.9, is in the lower class, it is lower than the industrial index | - All related stocks also increase. Chemicals industry +0.34% | - Target price KRW 30,000, has 53% disparate to increase compared with stock price. | - Institutions and Foreigners sell, Individuals buy | - Turnover Rate and Price Range both proper | - The main shareholding group is Individuals |
|
Compared with its close competitors within the same industry, KOSDAQ, the monthly volatility of Genic was around the average of that of its peer group, but the investment return for 1 month was at an absolutely low level. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -1.9%. As bearish stock price trend, the return-on-risk was poor, compared with its peer group. Moreover, compared with the KOSDAQ industry, the return-on-risk is below the industrial mean, -0.7, and thus it is hard to say that the industrial comparison performance was positive.
While institutions have been selling Genic during the past 7 trading days, foreigners have been buying during the past 3 trading days. As a shareholding sum by investor group for the past 4 weeks, foreigners have sold 28,905 shares with maintenance of a selling position and institutions have sold 29,987 shares with a selling trend. However, during the same period, individuals have bought 58,892 shares with an increasing position.
Cumulated shareholdings per investor group (1Mo) | | Total shareholdings per investor group |
| | |
By HeRo (
hero@heraldcorp.com)
This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.